Genzyme opts into Alnylam’s ALN-AT3 hemophilia program
The move marks first product opt-in since the companies formed an alliance in January last year to speed up and expand the development and commercialization of RNAi therapeutics
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.
The document provides guidance for the conduct of robust analyses to facilitate and speed up the development of new antibiotics, in particular those targeting multi-drug resistant bacteria. Comments
APP-111 showed efficacy in preclinical studies against hormone sensitive, castration resistant, as well as taxane resistant prostate cancer. In preclinical studies, the drug appeared to have less peripheral
VTP-43742 is the Company’s wholly owned and first-in-class ROR?t inhibitor product candidate for the treatment of autoimmune disorders, potentially including psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis and